Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.

Klein, Brad C; Miceli, Rosa; Severt, Lawrence; McAllister, Peter; Mechtler, Laszlo; McVige, Jennifer; Diamond, Merle; Marmura, Michael J; Guo, Hua; Finnegan, Michelle; Trugman, Joel M

Klein, Brad C; Miceli, Rosa; Severt, Lawrence; McAllister, Peter; Mechtler, Laszlo; McVige, Jennifer; Diamond, Merle; Marmura, Michael J; Guo, Hua; Finnegan, Michelle; Trugman, Joel M.

Afiliación

Klein BC; Abington Neurological Associates, Ltd., Abington, PA, USA.
Miceli R; AbbVie Inc., Madison, NJ, USA.
Severt L; AbbVie Inc., Madison, NJ, USA.
McAllister P; New England Institute for Neurology & Headache, Stamford, CT, USA.
Mechtler L; DENT Neurologic Institute, Amherst, NY, USA.
McVige J; DENT Neurologic Institute, Amherst, NY, USA.
Diamond M; Diamond Headache Clinic, Chicago, IL, USA.
Marmura MJ; Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Guo H; AbbVie Inc., Madison, NJ, USA.
Finnegan M; AbbVie Inc., Madison, NJ, USA.
Trugman JM; AbbVie Inc., Madison, NJ, USA.

Cephalalgia ; 43(1): 3331024221128250, 2023 01.

Article en En | MEDLINE | ID: mdl-36620892

Asunto(s)

Trastornos Migrañosos; Humanos; Resultado del Tratamiento; Método Doble Ciego; Trastornos Migrañosos/tratamiento farmacológico; Trastornos Migrañosos/prevención & control; Náusea

Palabras clave

Atogepant; clinical trial; long-term safety; migraine; preventive; tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trastornos Migrañosos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cephalalgia Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google